Human CD4+ CD25+ regulatory T cells suppress NKT cell functions

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4516-4520

  Azuma, Takeshi ^a   Takahashi, Tsuyoshi ^a   Kunisato, Atsushi ^a   Kitamura, Tadaichi ^a   Hirai, Hisamaru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4;

ARTICLE; CANCER IMMUNOTHERAPY; CELL CONTACT; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL CULTURE;

CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GALACTOSYLCERAMIDES; HUMANS; INTERFERON TYPE II; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS;

EID: 0041589414     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rosenberg, S. A., and White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol., 19: 81-84, 1996.
2. Hara, I., Takechi, Y., and Houghton, A. N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein, J. Exp. Med., 182: 1609-1614, 1995.
3. Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M., and Sherman, L. A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoiinmunity. J. Immunol., 160: 643-651, 1998.
4. Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., and Enk, A. H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med., 193: 1285-1294, 2001.
5. Levings, M. K., Sangregorio, R., and Roncarolo, M. G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med,. 193: 1295-1302, 2001.
6. Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., and Schuler, G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med., 193: 1303-1310, 2001.
7. Baecher-Allan, C., Brown, J. A., Freeman, G. J., and Hafler, D. A. CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol., 167: 1245-1253, 2001.
8. Ng, W. F., Duggan, P. J., Ponchel, F., Matarese, G., Lombardi, G., Edwards, A. D., Isaacs, J. D., and Lechler, R. I. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 98: 2736-2744, 2001.
9. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and Nakayama, E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res., 59: 3128-3133, 1999.
10. Shimizu, J., Yamazaki, S., and Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218, 1999.
11. Porcelli, S., Gerdes, D., Fertig, A. M., and Balk, S. P. Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4- and heterogeneous with respect to TCR beta expression. Hum Immunol., 48: 63-67, 1996.
12. Dellabona, P., Padovan, E., Casorati, G., Brockhaus, M., and Lanzavecchia, A. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J. Exp. Med., 180: 1171-1176, 1994.
13. Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., and Taniguchi, M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science (Wash. DC), 278: 1623-1626, 1997.
14. Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P., and Kronenberg, M. CDld-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution, J. Exp. Med., 188: 1521-1528, 1998.
15. Spada, F. M., Koezuka, Y., and Porcelli, S. A. CDld-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med., 188: 1529-1534, 1998.
16. Nieda, M., Nicol, A., Koezuka, Y., Kikuchi, A., Takahashi, T., Nakamura, H., Furukawa, H., Yabe, T., Ishikawa, Y., Tadokoro, K., and Juji, T. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CDld-restricted and Valpha24TCR-mediated manner. Hum. Immunol., 60: 10-19, 1999.
17. Takahashi, T., Chiba, S., Nieda, M., Azuma, T., Ishihara, S., Shibata, Y., Juji, T., and Hirai, H. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol., 168: 3140-3144, 2002.
18. Takahashi, T., Nieda, M., Koezuka, Y., Nicol, A., Porcelli, S. A., Ishikawa, Y., Tadokoro, K., Hirai, H., and Juji. T. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol., 164: 4458-4464, 2000.
19. Kawamura, T., Takeda, K., Mendiratta, S. K., Kawamura, H., Van Kaer, L., Yagita, H., Abo, T., and Okumura, K. Critical role of NKI+ T cells in IL-12-induced immune responses in vivo, J. Immunol., 160: 16-19, 1998.
20. Smyth, M. J., Thia, K. Y., Street, S. E., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., and Godfrey, D. I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp, Med., 191: 661-668, 2000.
21. Smyth, M. J., Taniguchi, M., and Street, S. E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol., 165: 2665-2670, 2000.
22. Spada, F. M., Borriello, F., Sugita, M., Watts, G. F., Koezuka, Y., and Porcelli, S. A. Low expression level but potent antigen presenting function of CDld on monocyte lineage cells. Eur. J. Immunol., 30: 3468-3477, 2000.
23. Fujimoto, S., Greene, M. I., and Sehon, A. H. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J. Immunol., 116: 791-799, 1976.
24. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp, Med., 155: 1063-1074, 1982.
25. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv. Immunol., 49: 281-355, 1991.
26. Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 101: 455-458, 2000.
27. Maloy, K. J., and Powrie, F. Regulatory T cells in the control of immune pathology. Nat. Immunol., 2: 816-822, 2001.
28. Denkers, E. Y., Scharton-Kersten, T., Barbieri, S., Caspar, P., and Sher, A. A role for CD4+ NKI.1 + T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection. J. Exp. Med., 184: 131-139, 1996.
29. Exley, M. A., Bigley, N. J., Cheng, O., Tahir, S. M., Smiley, S. T., Carter, Q. L., Stills, H. F., Grusby, M. J., Koezuka, Y., Taniguchi, M., and Balk, S. P. CDld-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J. Leukoc. Biol., 69: 713-718, 2001.
30. Apostolou, I., Takahama, Y., Belmant, C., Kawano, T., Huerre, M., Marchal, G., Cui, J., Taniguchi, M., Nakauchi, H., Fournie, J. J., Kourilsky, P., and Gachelin, G. Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc. Natl. Acad. Sci. USA. 96: 5141-5146, 1999.
31. Emoto, M., Emoto, Y., Buchwalow, I. B., and Kaufmann, S. H. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin. Eur. J. Immunol., 29: 650-659, 1999.
32. Gonzalez-Aseguinolaza, G., de Oliveira, C., Tomaska, M., Hong, S., Bruna-Romero, O., Nakayama, T., Taniguchi, M., Bendelac, A., Van Kaer, L., Koezuka, Y., and Tsuji, M. alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA, 97: 8461-8466, 2000.
33. Kawano, T., Nakayama, T., Kamada, N., Kaneko, Y., Harada, M., Ogura, N., Akutsu, Y., Motohashi, S., Iizasa, T., Endo, H., Fujisawa, T., Shinkai, H., and Taniguchi, M. Antitumor cytotoxicity mediated by ligand-activated human V α24 NKT cells. Cancer Res., 59: 5102-5105, 1999.
34. Tahir, S. M., Cheng, O., Shaulov, A., Koezuka, Y., Bubley, G. J., Wilson, S. B., Balk, S. P., and Exley, M. A. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol., 167: 4046-4050, 2001.
35. , Toura, I., Kawano, T., Akutsu, Y., Nakayama, T., Ochiai, T., and Taniguchi, M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J. Immunol., 163: 2387-2391, 1999.
36. Cederbom, L., Hall, H., and Ivars, F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol., 30: 1538-1543, 2000.